Supporting cardiovascular health
Cardiovascular health remains a global concern, and one of the reasons consumers seek protective benefits from dietary supplementation. As much as 80% of consumers in Europe and the US recognize the link between good heart health and overall health (FMCG Gurus).
For product developers and brands in nutraceutical, pharmaceutical, and functional food & beverage markets, MenaQ7® is a natural, clinically proven Vitamin K2 as MK-7 that supports cardiovascular health by activating Matrix Gla Protein (MGP), helping inhibit arterial stiffness and maintain vascular elasticity, while also offering validated bone-health benefits.
In recent years, there has been a strong focus on the role of arterial stiffness in cardiovascular health, as well as on the Vitamin K-dependent protein MGP, the most potent modulator of vascular calcification known, provided the body has enough Vitamin K2 to activate it.
MenaQ7® is the first and best clinically proven Vitamin K2 as MK-7 for cardiovascular health, supported by more than 22 published studies validating its benefits. A groundbreaking 3-year study showed that a nutritional dose of MenaQ7® taken daily decreased arterial stiffness by 14.2%, not only inhibiting age-related arterial stiffening but also promoting vascular elasticity.
Choose MenaQ7® to support your heart health claims with science.
Deep dive into MenaQ7 vitamin k2 for bone health
Significant research shows Vitamin K1 differs from K2 as MK-7 and MK-4, the active forms of Vitamin K2, with differing functional properties, and that natural fermentation–derived MenaQ7® K2 as MK-7 is the clinically validated form centered on bone health and cardiovascular health support because it plays a vital role in calcium metabolism by activating proteins involved in directing calcium into bones rather than letting it deposit in arteries and soft tissues. MenaQ7® activates osteocalcin, the K-dependent protein responsible for binding calcium within the bone matrix, supporting bone health.
